Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication

Summary

NM-702 oral tablets are being developed for the treatment of Intermittent Claudication, a primary early stage indication of peripheral arterial disease (PAD). This trial is designed to assess the safety and efficacy of 4 mg and/or 8 mg NM-702 taken twice a day (BID) for 24 weeks to see if it improves peak walking time (PWT) more than placebo for the treatment of Intermittent Claudication.

Timeline

Start

2003-04

Primary completion

—

Completion

2006-04

Drugs

Indications